S'abonner

Antibiotic Therapy and 48-Hour Mortality for Patients with Pneumonia - 17/08/11

Doi : 10.1016/j.amjmed.2006.04.017 
Eric M. Mortensen, MD, MSc a, b, , Marcos I. Restrepo, MD, MSc a, c, Antonio Anzueto, MD c, Jacqueline A. Pugh, MD a, b
a Veterans Evidence Based Research Dissemination and Implementation Center, South Texas Veterans Health Care System, San Antonio, Tex 
b Division of General Internal Medicine, South Texas Veterans Health Care System, San Antonio, Tex 
c Division of Pulmonary/Critical Care Medicine, South Texas Veterans Health Care System, San Antonio, Tex. 

Requests for reprints should be addressed to Eric Mortensen, MD, MSc, VERDICT, ALMD/UTHSCSA, Ambulatory Care (11C6), 7400 Merton Minter Boulevard, San Antonio, TX 78284.

Abstract

Purpose

Although numerous articles have demonstrated that recommended empiric antimicrobial regimens are associated with decreased mortality at 30 days, there is controversy over whether appropriate antibiotic selection has a beneficial impact on mortality within the first 48 to 96 hours after admission. Our aim was to determine whether the use of guideline-concordant antibiotic therapy is associated with decreased mortality within the first 48 hours after admission for patients with pneumonia.

Methods

A retrospective cohort study was conducted at two tertiary teaching hospitals in San Antonio, Texas. A propensity score was used to balance the covariates associated with the use of guideline-concordant antimicrobial therapy. A multivariable logistic regression model was used to assess the association between mortality within 48 hours and the use of guideline-concordant antibiotic therapy, after adjusting for potential confounders including the propensity score.

Results

Information was obtained on 787 patients with community-acquired pneumonia. The median age was 60 years, 79% were male, and 20% were initially admitted to the intensive care unit. At presentation 52% of subjects were low risk, 34% were moderate risk, and 14% were high risk. Within the first 48 hours, 20 patients died. After adjustment for potential confounders, the use of guideline-concordant antimicrobial therapy (odds ratio 0.37, 95% confidence interval, 0.14-0.95) was significantly associated with decreased mortality at 48 hours after admission.

Conclusion

Using initial empiric guideline-concordant antimicrobial therapy is associated with decreased mortality at 48 hours. Further research needs to investigate methods to ensure that patients with community-acquired pneumonia are treated with appropriate antimicrobial therapies.

Le texte complet de cet article est disponible en PDF.

Keywords : Antibacterial agents, Community-acquired infections, Pneumonia


Plan


 Dr. Mortensen was supported by a Department of Veteran Affairs Vertically Integrated Service Network 17 new faculty grant and a Howard Hughes Medical Institute faculty start-up grant 00378-001. Dr. Pugh was supported by Department of Veteran Affairs grants REA 05-129 and RCD 04-297. This material is the result of work supported with resources and the use of facilities at the South Texas Veterans Health Care System. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.


© 2006  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 119 - N° 10

P. 859-864 - octobre 2006 Retour au numéro
Article précédent Article précédent
  • Pulmonary Embolism in Patients with Chronic Obstructive Pulmonary Disease or Congestive Heart Failure
  • Manuel Monreal, Juan Francisco Sanchez Muñoz-Torrero, Virjanand S. Naraine, David Jiménez, Silvia Soler, Ramón Rabuñal, Pedro Gallego, RIETE Investigators
| Article suivant Article suivant
  • Impact of Guideline-Concordant Empiric Antibiotic Therapy in Community-Acquired Pneumonia
  • Christopher R. Frei, Marcos I. Restrepo, Eric M. Mortensen, David S. Burgess

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.